These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 1650698

  • 1. Mode of action of the new quinolones: new data.
    Hooper DC, Wolfson JS.
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [Abstract] [Full Text] [Related]

  • 2. Quinolone mode of action--new aspects.
    Hooper DC.
    Drugs; 1993 Apr; 45 Suppl 3():8-14. PubMed ID: 7689456
    [Abstract] [Full Text] [Related]

  • 3. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR, Malik M, Snyder M, Drlica K.
    J Mol Biol; 1996 May 17; 258(4):627-37. PubMed ID: 8636997
    [Abstract] [Full Text] [Related]

  • 4. Mode of action of the quinolone antimicrobial agents: review of recent information.
    Hooper DC, Wolfson JS.
    Rev Infect Dis; 1989 May 17; 11 Suppl 5():S902-11. PubMed ID: 2549608
    [Abstract] [Full Text] [Related]

  • 5. Quinolone mode of action.
    Hooper DC.
    Drugs; 1995 May 17; 49 Suppl 2():10-5. PubMed ID: 8549276
    [Abstract] [Full Text] [Related]

  • 6. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
    Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K.
    Antimicrob Agents Chemother; 1995 Jul 17; 39(7):1467-71. PubMed ID: 7492087
    [Abstract] [Full Text] [Related]

  • 7. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME.
    Am J Med; 1989 Nov 30; 87(5A):2S-8S. PubMed ID: 2574005
    [Abstract] [Full Text] [Related]

  • 8. Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis.
    Revel-Viravau V, Truong QC, Moreau N, Jarlier V, Sougakoff W.
    Antimicrob Agents Chemother; 1996 Sep 30; 40(9):2054-61. PubMed ID: 8878580
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of action of quinolones against Escherichia coli DNA gyrase.
    Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S.
    Antimicrob Agents Chemother; 1993 Apr 30; 37(4):839-45. PubMed ID: 8388200
    [Abstract] [Full Text] [Related]

  • 10. A class of gyrase mutants of Salmonella typhimurium show quinolone-like lethality and require rec functions for viability.
    Garí E, Figueroa-Bossi N, Blanc-Potard AB, Spirito F, Schmid MB, Bossi L.
    Mol Microbiol; 1996 Jul 30; 21(1):111-22. PubMed ID: 8843438
    [Abstract] [Full Text] [Related]

  • 11. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC.
    Clin Infect Dis; 1998 Aug 30; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [Abstract] [Full Text] [Related]

  • 12. Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV.
    Akasaka T, Onodera Y, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 1999 Mar 30; 43(3):530-6. PubMed ID: 10049263
    [Abstract] [Full Text] [Related]

  • 13. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Ishihara S, Kawada Y.
    J Antimicrob Chemother; 1997 Oct 30; 40(4):543-9. PubMed ID: 9372424
    [Abstract] [Full Text] [Related]

  • 14. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
    Strumberg D, Nitiss JL, Dong J, Walker J, Nicklaus MC, Kohn KW, Heddle JG, Maxwell A, Seeber S, Pommier Y.
    Antimicrob Agents Chemother; 2002 Sep 30; 46(9):2735-46. PubMed ID: 12183223
    [Abstract] [Full Text] [Related]

  • 15. Quinolone-resistant mutations of DNA gyrase increase sensitivity to acriflavine.
    Funatsuki K, Tanaka R, Inagaki S, Konno H, Katoh K, Nakamura H.
    Biol Pharm Bull; 1998 Jul 30; 21(7):667-72. PubMed ID: 9703246
    [Abstract] [Full Text] [Related]

  • 16. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones.
    Cullen ME, Wyke AW, Kuroda R, Fisher LM.
    Antimicrob Agents Chemother; 1989 Jun 30; 33(6):886-94. PubMed ID: 2548439
    [Abstract] [Full Text] [Related]

  • 17. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
    Barnard FM, Maxwell A.
    Antimicrob Agents Chemother; 2001 Jul 30; 45(7):1994-2000. PubMed ID: 11408214
    [Abstract] [Full Text] [Related]

  • 18. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE, Osheroff N.
    Curr Pharm Des; 2001 Mar 30; 7(5):337-53. PubMed ID: 11254893
    [Abstract] [Full Text] [Related]

  • 19. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J, Robicsek A, Hooper DC.
    Antimicrob Agents Chemother; 2006 Feb 30; 50(2):600-6. PubMed ID: 16436716
    [Abstract] [Full Text] [Related]

  • 20. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K, Zhao X.
    Microbiol Mol Biol Rev; 1997 Sep 30; 61(3):377-92. PubMed ID: 9293187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.